New York, March 5, 2026, 08:36 EST
- SEC filings revealed that Kenvue executives received new restricted stock unit grants effective March 2.
- The bulk of the awards will vest in three yearly chunks, stretching from 2027 to 2029.
- Kenvue’s disclosures arrive while the company pushes ahead with a planned acquisition by Kimberly-Clark.
Kenvue Inc’s senior leaders just reported fresh equity grants in filings, with the North America chief awarded 127,051 units, as the consumer health company moves closer to a takeover by Kimberly-Clark. 1 . 2
Kenvue’s filings are drawing attention right now, with the company in the midst of a deal. Kimberly-Clark in November announced plans to buy Kenvue via a cash-and-stock deal, aiming to build out a global health and wellness platform. The companies are shooting for a second-half 2026 close, pending necessary approvals and other conditions. 3 . 3
Restricted stock units, or RSUs, are a routine piece of compensation. Executives usually have to stick around for the awards to vest before they actually get the shares. The latest grants, disclosed this week, weren’t open-market purchases.
General Counsel Matthew Orlando disclosed receiving 122,286 RSUs, according to the filing, with the shares scheduled to vest in three equal chunks on March 2 of 2027, 2028, and 2029. 4 . 5
Anindya Dasgupta, who serves as group president for Asia-Pacific, was awarded a 98,994-unit grant, set to vest over three years, a separate filing shows. 6 . 7
Lawson Carlton, group president for EMEA and Latin America, reported a grant of 93,488 units, with vesting split into three equal portions from 2027 through 2029, according to the filing. 8 . 9
Michael Wondrasch, Kenvue’s chief tech and data officer, disclosed a grant of 79,407 units with matching vesting dates, according to a filing. 10 . 11
Heather Howlett, Kenvue’s vice president and chief accounting officer, picked up 22,233 RSUs, according to a filing. Out of that grant, 526 shares were withheld at $18.15 each to handle taxes related to the RSU vesting. 12 . 13
After dipping for two consecutive days earlier in the week, Kenvue ended March 4 at $18.19, ticking up 0.22%, historical pricing data show. 14 . 14
Kenvue, which emerged from Johnson & Johnson’s consumer health division, says sharpening execution is its top priority as it pursues the Kimberly-Clark deal. “As we look to 2026, we remain focused on continuing to enhance our performance,” CEO Kirk Perry told investors in February. 15 . 15
Still, the deal’s got baggage: Kenvue is contending with Tylenol litigation that won’t go away. A Texas judge just gave the green light for one lawsuit to move ahead; Kenvue’s response was that it plans to “vigorously defend” itself. 16 . 16
